Advanced cardiovascular life support is also referred as advanced cardiac life support is a set of clinical interventions for the emergency treatment of stroke and other life-threatening medical emergencies. According to WHO, more than 35% of the total global population were suffering from major or minor cardiovascular complication in 2015 and is the number one cause of death globally. Advanced cardiovascular life support is provided by well qualified health care personnel. The market growth of advanced cardiovascular life support is driven by the increasing number of cardiovascular diseases, coronary diseases and increasing demand for the emergency services. Other factors that propel the growth of market are continuous up gradation and modification of products, rising diabetic and obese population and excessive use of tobacco and alcohol. However, limited number of trained personnel has restrained of the growth of market.
The global advanced cardiovascular life support market is expected to grow at a CAGR of 7.0% during forecasted period 2017-2023.
Segmentation
Global advanced cardiovascular life support market is segmented on the basis of techniques, into airway management, non-invasive airway, endotracheal intubation, electrical therapy and lethal arrhythmias. On the basis of algorithm they are segmented into cardiac arrest, acute coronary syndromes, bradycardia, tachycardia, suspected stroke algorithms, and other. By instruments they are segmented into devices, accessories and other and on the basis of end users, the market is segmented into medical training centres, cardiac catheterization labs, hospital and other.
Key players for global advanced cardiovascular life support market
CPR Medical Devices, Inc. (Canada), Cardiac Science Corporation (US), General Electric Company (US), Koninklijke Philips N.V. (the Netherlands), Michigan Instruments (US), Physio-Control, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan)
Request Customization
Get a Sample
Get a Sample
Request Customization